USSTOCK.TODAY
Weekend. Closed Log in Sign up

Apellis Pharmaceuticals Inc(APLS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today

Halted
Trading Halted Since 2026-06-16: Trading has been halted. It may resume, and prices shown reflect the last trading day.
APLS
APLS
Halted
Apellis Pharmaceuticals Inc
$41.03
+0.00 +0.00%

Full metrics table

Index ⓘ -P/E ⓘ 41.01EPS (ttm) ⓘ 1Insider Own ⓘ 30.77%Shs Outstand ⓘ 127.9MPerf Week ⓘ -
Market Cap ⓘ 5.25BForward P/E ⓘ -EPS next Y ⓘ 74.86%Insider Trans ⓘ -0.31%Shs Float ⓘ 88.6MPerf Month ⓘ 0.1%
Enterprise Value ⓘ 5.32BPEG ⓘ -EPS next Q ⓘ -0.24Inst Own ⓘ 110.31%Short Float ⓘ 12.13%Perf Quarter ⓘ 89.6%
Income ⓘ 0.13BP/S ⓘ 4.75EPS this Y ⓘ -665%Inst Trans ⓘ -9.08%Short Ratio ⓘ 1.68Perf Half Y ⓘ 103.83%
Sales ⓘ 1.11BP/B ⓘ 12.65EPS next 5Y ⓘ 53.35%ROA ⓘ 14.1%Short Interest ⓘ 10.75MPerf YTD ⓘ 63.34%
Book/sh ⓘ 3.24P/C ⓘ 12.91EPS past 3/5Y ⓘ -ROE ⓘ 46.02%52W High ⓘ -0.27% ($41.14)Perf Year ⓘ 137.44%
Cash/sh ⓘ 3.18P/FCF ⓘ 140.18Sales past 3/5Y ⓘ 136.98% 31.98%ROIC ⓘ 16.87%52W Low ⓘ 154.84% ($16.10)Perf 3Y ⓘ -53.35%
Dividend Est. ⓘ -EV/EBITDA ⓘ 31.94EPS Y/Y TTM ⓘ 158.69%Gross Margin ⓘ 90.09%Volatility(W/M) ⓘ 0.13% 0.15%Perf 5Y ⓘ -10.1%
Dividend TTM ⓘ -EV/Sales ⓘ 4.81Sales Y/Y TTM ⓘ 42.46%Oper. Margin ⓘ 14.95%ATR (14) ⓘ 0.33Perf 10Y ⓘ -
Dividend Ex-Date ⓘ -Quick Ratio ⓘ 3.16EPS Q/Q ⓘ 119.32%Profit Margin ⓘ 12.06%RSI (14) ⓘ 84.48Recom ⓘ 3
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 3.63Sales Q/Q ⓘ 60.85%SMA20 ⓘ 0.14% ($40.97)Beta ⓘ -0.25Target Price ⓘ $41
Payout ⓘ -Debt/Eq ⓘ 1.15Earnings ⓘ 2026/2/24SMA50 ⓘ 26.8% ($32.36)Rel Volume ⓘ 0Prev Close ⓘ $41.03
Employees ⓘ 739LT Debt/Eq ⓘ 0.9EPS/Sales Surpr. ⓘ -25.67% 0.26%SMA200 ⓘ 58.68% ($25.86)Avg Volume(3M) ⓘ 6.42MPrice ⓘ $41.03
IPO ⓘ 2017/11/9Option/Short ⓘ Yes/NoTrades ⓘ 0Volume ⓘ -Change ⓘ -
Company
APLS APLSApellis Pharmaceuticals Inc | NASD | Biotechnology Deep dive

A commercial-stage biotech company that develops and markets therapeutics targeting the complement pathway of the immune system. It sells an ophthalmic injection for age-related retinal diseases and treatments for rare blood and kidney disorders. As a healthcare stock, its value is driven by core therapeutic revenue, label expansions, and the competitive landscape.

Quote

Over the past 1 year, on the higher side

0% below its 1-year high.

Now $41.03
52w low$16.1052w high$41.14
52W Range100%
Volume ⓘ 0

Traded less than usual. That is 0% of its average volume.

C
Overall · average, with some caution
We judged 6 of the 8 questions below. 1 rate excellent and 2 need caution.
No data for earnings, dividends, or not applicable.
ETFs holding this stock 5 ETFs

Multiple ETFs hold this stock, but only a sliver

Buying this ETF gives you exposure to this stock as well.

Peer comparison Biotechnology

It ranks #45 of 599 in the industry

Based on market cap of $5B.

FAQ

FAQ

APLS belongs to the Healthcare sector and operates in the Biotechnology industry.

The market cap of APLS is approximately $5.3B, ranking 1,352 within its sector.

APLS has a P/E ratio of approximately 41.0x, which can be used to assess its valuation relative to the Healthcare sector average.

APLS has recorded a 52-week high of $41.14 and a low of $16.10.

Telegram KakaoTalk
Briefs · earnings · signals, first Telegram · KakaoTalk channels